LLY vs SIGA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
SIGA presents a stark contrast between a pristine balance sheet and a collapsing operational core, evidenced by a Piotroski F-Score of 4/9 (Stable). While the company maintains zero debt and an exceptional current ratio of 11.83, the YoY revenue decline of -95.30% and an operating margin of -250.38% indicate a severe crisis in business continuity. The current price of $4.76 trades at a premium to both the Graham Number ($4.47) and the Intrinsic Value ($2.24), suggesting the stock is overvalued relative to its fundamentals. Technical trends are fully bearish, and the earnings track record shows a consistent failure to meet analyst expectations.
Compare Another Pair
Related Comparisons
LLY vs SIGA: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and SIGA Technologies, Inc. (SIGA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.